Cargando…
A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer
BACKGROUND & OBJECTIVES: Screening for hepatitis B prior to the initiation of chemotherapy in patients with cancer is recommended by all major hepatology and oncology societies. This study was aimed to determine the screening practices for hepatitis B among oncologists from India and their exper...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602929/ https://www.ncbi.nlm.nih.gov/pubmed/32719235 http://dx.doi.org/10.4103/ijmr.IJMR_2327_18 |
_version_ | 1783603800329682944 |
---|---|
author | Sundaram, Sridhar Patil, Prachi Sengar, Manju Rathod, Raosaheb Mehta, Shaesta |
author_facet | Sundaram, Sridhar Patil, Prachi Sengar, Manju Rathod, Raosaheb Mehta, Shaesta |
author_sort | Sundaram, Sridhar |
collection | PubMed |
description | BACKGROUND & OBJECTIVES: Screening for hepatitis B prior to the initiation of chemotherapy in patients with cancer is recommended by all major hepatology and oncology societies. This study was aimed to determine the screening practices for hepatitis B among oncologists from India and their experience with hepatitis B reactivation. METHODS: A questionnaire-based survey was conducted among oncologists attending the Evidence-Based Medicine Conference at Tata Memorial Centre, Mumbai, India. The questionnaire was developed in keeping with the recent guidelines for hepatitis B reactivation on chemotherapy, with questions regarding demographics, years in practice and hepatitis B screening practices and management. There was 78 per cent response rate to the questionnaire. RESULTS: Most respondents were <35 yr of age (69%), with <five years of experience (39%), practicing in an academic institution (81%). Seventy four per cent respondents always screened their patients with cancer for hepatitis prior to chemotherapy, whereas 19 per cent in special settings and seven per cent never screened; 96 per cent respondents used hepatitis B surface antigen (HBsAg) as a screening test, while 17 per cent also used antibody to hepatitis B core antigen. Sixty one per cent respondents used entecavir or tenofovir for prophylaxis; 70 per cent continued prophylaxis till 6-12 months after completion of chemotherapy, while 21 per cent continued only till the end of chemotherapy. INTERPRETATION & CONCLUSIONS: More than 25 per cent of the oncologists were not screening their patients with cancer for viral hepatitis prior to cancer-directed therapy, and only 17 per cent of the oncologists used the recommended tests for screening. Better training of oncologists regarding viral hepatitis screening and management is needed. |
format | Online Article Text |
id | pubmed-7602929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-76029292020-11-04 A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer Sundaram, Sridhar Patil, Prachi Sengar, Manju Rathod, Raosaheb Mehta, Shaesta Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Screening for hepatitis B prior to the initiation of chemotherapy in patients with cancer is recommended by all major hepatology and oncology societies. This study was aimed to determine the screening practices for hepatitis B among oncologists from India and their experience with hepatitis B reactivation. METHODS: A questionnaire-based survey was conducted among oncologists attending the Evidence-Based Medicine Conference at Tata Memorial Centre, Mumbai, India. The questionnaire was developed in keeping with the recent guidelines for hepatitis B reactivation on chemotherapy, with questions regarding demographics, years in practice and hepatitis B screening practices and management. There was 78 per cent response rate to the questionnaire. RESULTS: Most respondents were <35 yr of age (69%), with <five years of experience (39%), practicing in an academic institution (81%). Seventy four per cent respondents always screened their patients with cancer for hepatitis prior to chemotherapy, whereas 19 per cent in special settings and seven per cent never screened; 96 per cent respondents used hepatitis B surface antigen (HBsAg) as a screening test, while 17 per cent also used antibody to hepatitis B core antigen. Sixty one per cent respondents used entecavir or tenofovir for prophylaxis; 70 per cent continued prophylaxis till 6-12 months after completion of chemotherapy, while 21 per cent continued only till the end of chemotherapy. INTERPRETATION & CONCLUSIONS: More than 25 per cent of the oncologists were not screening their patients with cancer for viral hepatitis prior to cancer-directed therapy, and only 17 per cent of the oncologists used the recommended tests for screening. Better training of oncologists regarding viral hepatitis screening and management is needed. Wolters Kluwer - Medknow 2020-06 /pmc/articles/PMC7602929/ /pubmed/32719235 http://dx.doi.org/10.4103/ijmr.IJMR_2327_18 Text en Copyright: © 2020 Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Sundaram, Sridhar Patil, Prachi Sengar, Manju Rathod, Raosaheb Mehta, Shaesta A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer |
title | A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer |
title_full | A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer |
title_fullStr | A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer |
title_full_unstemmed | A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer |
title_short | A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer |
title_sort | survey of clinical practices among oncologists regarding hepatitis b screening in patients with cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602929/ https://www.ncbi.nlm.nih.gov/pubmed/32719235 http://dx.doi.org/10.4103/ijmr.IJMR_2327_18 |
work_keys_str_mv | AT sundaramsridhar asurveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT patilprachi asurveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT sengarmanju asurveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT rathodraosaheb asurveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT mehtashaesta asurveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT sundaramsridhar surveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT patilprachi surveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT sengarmanju surveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT rathodraosaheb surveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer AT mehtashaesta surveyofclinicalpracticesamongoncologistsregardinghepatitisbscreeninginpatientswithcancer |